Liminatus Pharma, Inc. reported a net loss for Q1 2026 with current liabilities slightly exceeding current assets, underscoring ongoing liquidity challenges. The company is actively addressing Nasdaq listing deficiencies tied to minimum market value thresholds, with a compliance deadline by May 2026, adding pressure on near-term operational and capital strategies. Recent capital raises have bolstered cash positions, while management explores regulated digital asset strategies as part of treasury optimization. However, a lack of disclosed proprietary products or market positioning leaves Liminatus in an uncertain competitive stance within the pharmaceutical sector. The company’s path forward hinges on successful compliance, capital access, and clarity on product development progress.